medigraphic.com
Boletín Clínico de la Asociación Médica del Hospital Infantil del Estado de Sonora

2010, Number 2

<< Back Next >>

Bol Clin Hosp Infant Edo Son 2010; 27 (2)

Síndrome de Kawasaki. Activación de BCG. Presentacion de un Caso Clínico

Covarrubias-Espinoza R, Franco-Hernández R, Manzo-Ríos MA, López-Armenta G, Hinojosa-Guadarrama F, Martínez-Chávez MC, Pineda-Feliz H, Millán-Gianini OP

Language: Spanish
References: 14
Page: 122-124
PDF size: 87.16 Kb.


ABSTRACT

The Kawasaki syndrome or disease (EK) is an acute, self-limited, febrile, multisystemic vasculitis, which affects young children. Described for the first time in 1967, by Tomisaku Kawasaki in Tokyo, Japan. Distributed in Europe and American territory probably, due to the knowledge and diagnosis of the disease. It affects little children, 50% of the patients are 2 years old or younger; is rare in children older than 8 years or less of 3 months old. Is more frequent in boys than girls, 1.5:1 relation. The annual incidence is 4,000 to 8,000 children affected in the USA.
At the beginning it was thought as a benign exanthema; but, the fever can be long-lasting and there could be cardiac compromise, especially coronary aneurism, which can lead to acute myocardial infarction and sudden dead.
This is the clinical case of a two year old boy with Kawasaky disease. With a positive BCG peripheral reaction that will enrich the criteria of diagnosis of these disease.


REFERENCES

  1. Kawasaki T; kasaki F; Okawa S, et al: A new infantile acute febril mucocutaneous lymph node síndrome (MLNS) prevailing in japan. Pediatrics, 54: 271-276, 1974.

  2. Melish M. E. Kawasaki síndrome ( the mucocutaneous lymph node síndrome) Ann. Rev, Med. 33: 569-585, 1982.

  3. Ministry of Health and Welfore, report from MCLS. Research Committee 1971-72. Tokyo, japanese Govemment, 1972. Pp. 9-10.

  4. Laupland KB, Dele Davies H. Epidemiology, Etiology, and Management of Kawasaki Disease: State of the art. Pediatr Cardiol 1999; 20: 177-83.

  5. Garcia-Pavon S, Staines-Boone,Hernandez-Bautista V, Yamasaki N M. Reactivacion de vacuna BCG en la enfermedad de Kawasaki: Caso clìnico y revision de bibliografia.Rev Alergia de Mex 2006; 53(2): 76-8.

  6. Burgos A F, Vega C, Stella Cicono, González G. Síndrome de Kawasaki. Revista de postgrado de la cátedra vía medicina N0. 107- agosto/2001 pp: 34-5.

  7. Banfi A. Enfermedad de Kawasaki. Rev Chil Pediatr 2001; 76(6): 487-95.

  8. Rowlay AH, Shulman ST. Kawasaki Syndrome. Clin Microbiol Rev 1998; 11(3): 405-14.

  9. Rowley AH, Shulman ST. Sindrome de Kawasaki. Clin Ped NA 1999; 2: 341-59.

  10. Wright Da, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids, J Pediatr 1996; 128: 146-9.

  11. Venglarick JS, Mouhab A. Severe thrombocytopenia as a presenting manifestation of Kawasaki disease. Arch Pediatr Adolesc Med 1995; 149: 215-6.

  12. Burns JC, Kushner HI, Bastian JF, Sjike H1, Sjike H, Shimizu C, Matsubara T, et al. Kawasaki Disease: a brief history. Pediatrics 2000; 106 (2): 27.

  13. Sotelo N, Gonzalez LA. Kawasaki disease: A rare pediatric pathology in Mexico Twenty cases report from the Hospital Infantil del Estado de Sonora. Arch Cardiol Mex 2007, 77: 299-307.

  14. Nomura Y, Masuda K, Yoshinaga M, Semeshima K, Miyata K. Patients diagnosed with Kawasaki disease before the fifth day of illness have a higher risk of coronary artery aneurysm. Pediatrics International 2002; 44: 353-7.




2020     |     www.medigraphic.com